Lipoprotein (a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement

F Kronenberg, S Mora, ESG Stroes… - European heart …, 2022 - academic.oup.com
Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

Heart disease and stroke statistics—2022 update: a report from the American Heart Association

CW Tsao, AW Aday, ZI Almarzooq, A Alonso… - Circulation, 2022 - Am Heart Assoc
Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

[HTML][HTML] Small interfering RNA to reduce lipoprotein (a) in cardiovascular disease

ML O'Donoghue, RS Rosenson… - … England Journal of …, 2022 - Mass Medical Soc
Background Lipoprotein (a) is a presumed risk factor for atherosclerotic cardiovascular
disease. Olpasiran is a small interfering RNA that reduces lipoprotein (a) synthesis in the …

Heart disease and stroke statistics—2023 update: a report from the American Heart Association

CW Tsao, AW Aday, ZI Almarzooq, CAM Anderson… - Circulation, 2023 - Am Heart Assoc
Background: The American Heart Association, in conjunction with the National Institutes of
Health, annually reports the most up-to-date statistics related to heart disease, stroke, and …

2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association

SS Martin, AW Aday, ZI Almarzooq, CAM Anderson… - Circulation, 2024 - Am Heart Assoc
BACKGROUND: The American Heart Association (AHA), in conjunction with the National
Institutes of Health, annually reports the most up-to-date statistics related to heart disease …

Lipoprotein (a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart …

G Reyes-Soffer, HN Ginsberg, L Berglund… - … , and vascular biology, 2022 - Am Heart Assoc
High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

The changing landscape of atherosclerosis

P Libby - Nature, 2021 - nature.com
Emerging evidence has spurred a considerable evolution of concepts relating to
atherosclerosis, and has called into question many previous notions. Here I review this …

2020 ACC/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Joint …

Writing Committee Members, CM Otto… - Journal of the American …, 2021 - jacc.org
The recommendations listed in this document are, whenever possible, evidence based. An
extensive review was conducted on literature published through March 1, 2020. Searches …

[PDF][PDF] Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the …

J Boren, MJ Chapman, RM Krauss… - European heart …, 2020 - academic.oup.com
OP-EHEA191011_online 2313..2340 Page 1 Low-density lipoproteins cause atherosclerotic
cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus …

Heart disease and stroke statistics—2019 update: a report from the American Heart Association

EJ Benjamin, P Muntner, A Alonso, MS Bittencourt… - Circulation, 2019 - Am Heart Assoc
Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …